Esperion Therapeutics sees surge in stock price on better-than-expected quarterly results

From Stocktwits: 2025-03-04 22:48:16

Esperion Therapeutics CEO Sheldon Koenig is optimistic about driving revenue gains and achieving profitability by expanding bempedoic acid products in the U.S. and Europe, and entering key global markets. The company’s shares surged 12% after reporting a better-than-expected quarterly loss of $0.11 per share and revenue of $69.1 million, exceeding estimates. Esperion’s NEXLETOL and NEXLIZET were added to the U.S. Department of Defense’s Uniform Formulary, covering nine million lives. The company also expanded its prescriber base and is developing triple-combination products with promising LDL-C reductions. Otsuka Pharmaceutical submitted a New Drug Application for bempedoic acid in Japan. Analysts maintain a bullish outlook on Esperion’s stock.



Read more at Stocktwits: Esperion Therapeutics Retail Bulls Charge In As Stock Notches Best Day In 3 Months On Impressive Q4